FIELD: biotechnology.
SUBSTANCE: monoclonal antibody is proposed, specific for legumain, characterised in that the heavy chain is characterised by amino-acid residue 28-463 of the amino acid sequence of SEQ ID NO: 1, the light chain is characterised by amino-acid residue 28-245 of amino acid sequence of SEQ ID NO: 2, the antibody is used as active ingredient for oncotherapy, as well as polynucleotides encoding each of the said chains of the antibody.
EFFECT: invention enables to obtain the antibody having high affinity to the antigen, low immunogenicity and high cytotoxicity, which may be produced in large quantities in a short period of time.
5 cl, 11 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2013 |
|
RU2551235C2 |
| ANTIBODIES AGAINST CCR7 RECEPTOR FOR CANCER TREATMENT | 2006 |
|
RU2404808C2 |
| ANTIBODY SELECTIVE TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR, AND USES THEREOF | 2001 |
|
RU2298013C2 |
| ANTIBODY SELECTIVE TO RECEPTOR APOPTOSIS-INDUCING LIGAND AND ASSOCIATED WITH TUMOR NECROSIS FACTOR AND ITS USING | 2002 |
|
RU2313537C2 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2015 |
|
RU2611685C2 |
| COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
| HUMANIZED ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND METHODS FOR USE IN ANTITUMOR THERAPY | 2014 |
|
RU2761662C2 |
| ANTIBODIES RECOGNISING CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS, AND METHODS OF USING SUCH | 2007 |
|
RU2461572C2 |
| ANTIBODIES RECOGNIZING CARBOHYDRATE-CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS OF APPLICATION | 2012 |
|
RU2616868C2 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
